Year: 2025

Mr. Wilson has a Track Record of Leading Product Launches and Achieving Revenue Growth in the Endovascular Devices Market BRAINTREE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, is continuing its transition into a commercially focused company with the election of David J. Wilson to the Board of Directors. Mr. Wilson is a seasoned healthcare executive with a background of commercial success and revenue growth in the endovascular devices market. Mr. Wilson’s career spans over 30 years and includes broad, global leadership expertise in business strategy and operations, R&D, commercial readiness and product launches. He dedicated two decades in roles of increasing responsibility with various Johnson and Johnson (J&J) companies,...

WISeKey’s Subsidiary, WISeSat.Space to Launch a New-Generation Satellite on January 14, a Significant Milestone in the Creation of a Global Satellite Constellation Geneva, Switzerland – January 13, 2025 – WISeKey International Holding (“WISeKey” or the “Company”) (NASDAQ: WKEY; SIX: WIHN), a leading global cybersecurity, AI, and IoT company, today announced that its subsidiary WISeSat.Space, on January 14, 2025 will launch a new-generation satellite, an innovative system designed to provide comprehensive Earth IoT coverage with ultra-low latency, enabling real-time tracking and monitoring of trillions of IoT devices. These satellites incorporate advanced technology to deliver secure and scalable global connectivity, addressing critical concerns around data security, privacy, and geopolitical neutrality. By leveraging Switzerland’s neutrality,...

Riyadh, Saudi Arabia, Jan. 13, 2025 (GLOBE NEWSWIRE) —   SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company specializing in Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced that in partnership with its parent company, WISeKey International Holding (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), is scaling its presence in Saudi Arabia to support the Kingdom’s digital transformation and cybersecurity advancements. Through their joint venture, WISeKey Arabia, in collaboration with the Juffali Group, SEALSQ and WISeKey aim to gradually introduce groundbreaking technology innovations tailored to Saudi Arabia’s unique needs. In 2019, WISeKey Arabia, in partnership with the Juffali Group, a leading Saudi business conglomerate, is committed to fostering a secure...

The investment commitment is in the form of a share subscription facility from GEM Global Yield LLC SCS (“GGY”) and is subject to a separate listing of Caret Digital on a Canadian stock exchange GGY’s shareholding will be capped at 9.9% Funds will be invested at the Caret Digital subsidiary level and hence non-dilutive for VivoPower shareholders Funds from the investment will be used to execute upon Caret Digital’s Power-to-X strategy (“P2X”) which seeks to activate the highest and best use cases for renewable power capacity First phase of Caret Digital’s P2X strategy is building out capacity including data centre infrastructure for DOGE coin mining Second phase of Caret Digital’s P2X strategy is AI enabled data centres DOGE coin mining is consistent with Caret Digital’s Power-to-X strategy that seeks to activate the highest and best...

Company has invested $24 billion with local suppliers since 2010, creating and sustaining 92,000 Michigan jobsDTE invests with Michigan businessesDetroit Voltage founder and CEO Deana NeelyDetroit, Jan. 13, 2025 (GLOBE NEWSWIRE) — For Detroit Voltage, a Detroit-based energy projects and electric infrastructure company, becoming a DTE supplier has been a game changer. Since last spring, Detroit Voltage has installed hundreds of EV charging stations on behalf of DTE. Founder and CEO Deana Neely says the consistent pipeline of opportunities shines a positive light on her community-focused, forward-thinking business. Recently, Detroit Voltage won a contract to provide public safety and field support in the aftermath of large storms. They are currently staffing up for this new contract. “The benefits of our collaboration...

Silexion to present SIL-204 data at leading Cancer Symposium designed to feature the latest science in the field of GI cancers Cayman Islands, January 13, 2025 — Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that it will be presenting a poster at the 2025 ASCO Gastrointestinal (GI) Cancers Symposium taking place January 23-25, 2025, in San Francisco, California. The 2025 ASCO Gastrointestinal Cancers Symposium is a specialized meeting designed to highlight the latest science in GI cancers and other information oncologists of all subspecialties need to know now, in order to provide the highest quality of care to patients. Silexion’s abstract will be published on the ASCO Gastrointestinal Cancers...

TORONTO, Jan. 13, 2025 (GLOBE NEWSWIRE) — Celestica’s (TSX: CLS) (NYSE: CLS) fourth quarter financial results and conference call will take place on Thursday, January 30. The conference call start time is 8:00am ET. Financial results will be released after market close on Wednesday, January 29. Participants are invited to join the live webcast at the following link. For those unable to participate, a recorded webcast will be available approximately two hours after completion of the call. To access the recorded webcast visit www.celestica.com. Contact Celestica Investor Relationsclsir@celestica.com

– ARCALYST® (rilonacept) 2024 net product revenue of $416.4 million (unaudited), representing ~79% year-over-year growth –– ARCALYST 2025 net product revenue expected to be $560 – $580 million –– Kiniksa expects to remain cash flow positive on an annual basis – LONDON, Jan. 13, 2025 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported preliminary unaudited fourth quarter and full year 2024 ARCALYST net product revenue and provided 2025 ARCALYST net product revenue guidance. “ARCALYST uptake in recurrent pericarditis continues to grow. As of the end of 2024, approximately 13% of the multiple-recurrence target population...